Pfizer Sets Its Sights On Therapeutic Cancer Vaccines
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The big pharma, which has failed to keep up with rivals in the immuno-oncology field, plans to bring a therapeutic cancer vaccine into the clinic in the next 18 to 24 months, vaccine R&D head Emilio Emini said during a media briefing at the company’s headquarters Sept. 10.